Truvian’s automated TruVerus system for chemistry, immunoassay and hematology testing is designed to turn around multiple results in about 30 minutes from a single tube sample, while the patient is still on-site.
This past January, TruVerus picked up FDA clearances for offering complete blood counts as well as nine separate metabolic, cardiovascular and liver health analyses. The agency greenlit the instrument itself the month before, along with a kidney panel.
The in vitro diagnostic system includes a cell imager plus an absorbance reader and a bead scanner, with an automated pipettor and onboard centrifuge that can run single-use consumable reagent kits. Truvian aims to place its platform into health systems and doctors’ offices as well as retail pharmacy locations and clinical research sites.
“Partnering with Siemens Healthineers represents an important milestone for Truvian and strong validation of both the TruVerus platform and the market opportunity we are pursuing,” Truvian’s founder and chief operating officer, Dr. Dena Marrinucci, said in a statement.
“Siemens Healthineers brings world-class experience developing, manufacturing, and commercializing diagnostic technologies at global scale,” Marrinucci added. “Bringing that expertise together with Truvian’s platform can help us accelerate development, expand our capabilities, and ultimately bring high-quality testing to a broader range of healthcare settings.”
The terms of the deal were not disclosed, but Siemens Healthineers said it will provide technical resources and commercial guidance, and that the two companies will explore the development of future diagnostics together.
“The goal of our alliance is to expand patient access to testing,” said Dirk Heckel, Siemens Healthineers’ chief technology officer for diagnostics. “By combining Truvian’s innovative TruVerus platform with our diagnostics expertise and global reach, we see an opportunity to advance innovation and provide the right test, at the right time, in the most convenient way possible.”
Late last month, Siemens Healthineers inked a deal with Novo to advance its own blood test for measuring fibrosis in patients with hidden liver diseases.
